RxDoctor Payments Data

Lester Robertson, MD

Hematology & Oncology · Savannah, GANPI 1902810500

Payments from drug & device makers

$18,038in general payments, 2019–2025

Across 882 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • Merck$1K
  • Amgen$985
  • Pfizer$917
  • AstraZeneca$872
  • E.r. Squibb & Sons, L.L.C.$685
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$15,80388%
  • Education$1981%
  • Gifts$2,03711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis117$3,839
Merck62$1,264
Amgen51$985
Pfizer59$917
AstraZeneca(2 entities)50$872
E.r. Squibb & Sons, L.L.C.44$685
Regeneron Healthcare Solutions, Inc.34$670
Genentech USA, Inc.41$670
Johnson & Johnson(2 entities)32$614
Gilead(2 entities)30$596
Daiichi Sankyo Inc.29$534
Bristol Myers Squibb22$424
Sanofi19$413
Lilly USA, LLC17$346
Seagen Inc.21$345
Astellas Pharma US Inc19$339
AbbVie17$327
Eisai Inc.17$299
Takeda Pharmaceuticals U.S.A., Inc.11$272
Bayer13$242
GSK12$223
Ipsen Biopharmaceuticals, Inc11$219
Array Biopharma Inc13$216
Acrotech Biopharma Inc.11$210
Beigene USA, Inc.9$182
Incyte Corporation9$150
Puma Biotechnology, Inc.8$143
Exelixis Inc.7$130
Stemline Therapeutics Inc.5$127
EMD Serono, Inc.5$125
Pharmacyclics LLC, An Abbvie Company6$108
Taiho Oncology, Inc.5$105
Boehringer Ingelheim5$104
Jazz Pharmaceuticals Inc.5$84
Rigel Pharmaceuticals, Inc.4$79
Tersera Therapeutics LLC4$75
Beone Medicines USA, Inc.3$72
Tesaro, Inc.4$71
Deciphera Pharmaceuticals Inc.3$69
Myovant Sciences Inc.3$68
Kyowa Kirin, Inc.3$66
Sumitomo Pharma America, Inc.3$61
Sobi, Inc3$57
Geron Corporation2$52
ADC Therapeutics America, Inc.2$45
Morphosys, US Inc.3$43
Karyopharm Therapeutics Inc.2$41
G1 Therapeutics, Inc.2$37
Mylan Institutional Inc.2$33
Sun Pharmaceutical Industries Inc.2$32
Clovis Oncology, Inc.2$31
Dova Pharmaceuticals2$31
AMAG Pharmaceuticals, Inc.2$29
Global Blood Therapeutics, Inc.2$27
CSL Behring1$25
Pharmacosmos Therapeutics Inc.1$25
Heron Therapeutics, Inc.1$24
EUSA Pharma (US) LLC1$22
Teva Pharmaceuticals USA, Inc.1$20
Octapharma USA, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,038 in reported general payments places this provider in the 60th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$235,570
Medicare patients
439
Services billed
22,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide39$622,758
PomalystPomalidomide35$587,685
CalquenceAcalabrutinib Maleate27$409,892
IbrancePalbociclib17$276,021
ErleadaApalutamide17$256,355
XtandiEnzalutamide14$192,290
Abiraterone Acetate42$64,866
Gamunex-CImmune Globul G/Gly/Iga Avg 4639$50,049
OrgovyxRelugolix15$38,458
XareltoRivaroxaban17$18,419
EliquisApixaban17$11,174
Exemestane29$4,588
Anastrozole147$1,926
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen89$1,338
Tamoxifen Citrate49$845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$685$587,68535 claims
AstraZenecaCalquence$872$409,89227 claims
PfizerIbrance, Eliquis$917$287,19534 claims
Johnson & JohnsonErleada, Xarelto$614$274,77334 claims
Astellas Pharma US IncXtandi$339$192,29014 claims
Sumitomo Pharma America, Inc.Orgovyx$61$38,45815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →